Fluconazole
- Generic Name
- Fluconazole
- Brand Names
- Diflucan
- Drug Type
- Small Molecule
- Chemical Formula
- C13H12F2N6O
- CAS Number
- 86386-73-4
- Unique Ingredient Identifier
- 8VZV102JFY
- Background
Fluconazole, commonly known as Diflucan, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an azole antifungal, in the same drug family as ketoconazole and itraconazole. Fluconazole has many advantages over the other antifungal dr...
- Indication
Fluconazole can be administered in the treatment of the following fungal infections:
1) Vaginal yeast infections caused by Candida
2) Systemic Candida infections
3) Both esophageal and oropharyngeal candidiasis
4) Cryptococcal meningitis
5) UTI (urinary tract infection) by Candida
6) Peritonitis (inflammation of the peritoneum) caused by Candida
...
- Associated Conditions
- Candida intertrigo, Candida pneumonia, Candida urinary tract infection, Candidemia, Candidiasis, Coccidioidomycosis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Meningitis, Cryptococcal, Oropharyngeal Candidiasis, Peritoneal candidiasis, Pneumonia cryptococcal, Pruritus, Skin Irritation, Systemic Candida Infections caused by Candida, Vaginal Candidiasis, Disseminated Candidiasis
- Associated Therapies
- -
Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis
- Conditions
- Interventions
- First Posted Date
- 2024-11-29
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 248
- Registration Number
- NCT06709196
- Locations
- 🇩🇰
Department of Urology, Aalborg University Hospital, Aalborg, Denmark
🇩🇰Department of Urology, Aarhus University Hospital, Aarhus, Denmark
🇩🇰Department of Urology, Rigshospitalet, Copenhagen, Denmark
A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-05-10
- Target Recruit Count
- 50
- Registration Number
- NCT06345794
- Locations
- 🇺🇸
ICON San Antonio Clinical Research Unit, San Antonio, Texas, United States
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 120
- Registration Number
- NCT06274554
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
Comparison of Efficacy of Single Oral Dose Fluconazole and Itraconazole in Patients With Pityriasis Versicolor
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Combined Military Hospital Abbottabad
- Target Recruit Count
- 164
- Registration Number
- NCT05862714
- Locations
- 🇵🇰
CMH Abbottabad, Abbottābād, Khyber Pakhtunkhwa, Pakistan
Efficacy of Prophylactic Fluconazole Therapy in Preterm and Very Low Birth Weight Neonates in Preventing Invasive Fungal Infection.
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2023-05-08
- Lead Sponsor
- Services Institute of Medical Sciences, Pakistan
- Target Recruit Count
- 110
- Registration Number
- NCT05848492
- Locations
- 🇵🇰
Services Hospital Lahore, Lahore, Punjab, Pakistan
Population Pharmacokinetics of Fluconazole in the Treatment of Neonatal Fungal Infectious Disease
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Beijing Children's Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT05775692
- Locations
- 🇨🇳
Beijing Children's Hospital of Capital Medical University, Beijing, Beijing, China
Study to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy Subjects
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2022-08-30
- Lead Sponsor
- Concert Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT05478772
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
Clinical Study of ABCD in the Treatment of Cryptococcal Meningitis
- Conditions
- Interventions
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05471063
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
- Conditions
- Interventions
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 450
- Registration Number
- NCT05421858
- Locations
- 🇺🇸
Washington University School of Medicine, Infectious Diseases Clinical Research Unit, Saint Louis, Missouri, United States
🇺🇸University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸Houston Methodist Hospital - Texas Medical Center, Houston, Texas, United States
The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis Symptoms
- Conditions
- Interventions
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Maastricht University Medical Center
- Target Recruit Count
- 252
- Registration Number
- NCT05367089
- Locations
- 🇳🇱
Zuyderland Medical Centre, Heerlen, Netherlands
🇳🇱MaastrichtUMC, Maastricht, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.